Corline Biomedical AB Stock Price

OM:CLBIO Community·SEK 386.8m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

Create a narrative

CLBIO Share Price Performance

SEK 18.00

10.76 (148.62%)

SEK 18.00

10.76 (148.62%)

SEK 18.00

Wed, 3 Dec 25

Share Pricen/a

CLBIO Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

High growth potential with adequate balance sheet.

4 Risks

1 Reward

View Full Analysis

Corline Biomedical AB Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -1.11
: 70.23%
: -268.44%
: 0%

View Full Analysis

About CLBIO

Founded: 1991
Employees: 13
CEO: Henrik Nittmar
WebsiteView website: www.corline.se

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.